I-Mab has begun the new year with a pipeline pivot, pausing work on an asset Sanofi bought into last year to focus on its play for the congested CLDN18.2 space. Uliledlimab is the asset I-Mab has ...

CEO and Board Member of I-Mab. “Building on this positive momentum, the company has implemented a portfolio prioritization to support the accelerated development of givastomig.” The company ...

After hours: January 29 at 5:19:24 PM EST Loading Chart for IMAB ...

The layoffs follow an announcement in early January that I-Mab will re-prioritize resources to focus on advancing a CLDN18.2 and 4-1BB bispecific antibody for gastric cancers. I-Mab will cut 27% of ...

CEO and Board Member of I-Mab. "Building on this positive momentum, the Company has implemented a portfolio prioritization to support the accelerated development of givastomig." Givastomig (TJ033721 / ...

Jan. 8, 2025 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, ...

At close: January 29 at 3:52:56 PM EST ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

1 Day AUB 1.28% DJIA 0.31% S&P 500 0.92% Financial Services -0.42% ...